Literature DB >> 15623653

Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells.

Yan Xiao1, Constance L Monitto, Khalid M Minhas, David Sidransky.   

Abstract

The molecular mechanism of lactoferrin-induced cell growth inhibition is incompletely understood. Studying head and neck cancer cells treated with human lactoferrin, we observed growth arrest in three of four cell lines tested. This growth arrest was caused by cell cycle inhibition at the G0-G1 checkpoint. Lactoferrin-induced growth inhibition was associated with a large increase in p27 protein, accompanied by decreased phosphorylation of retinoblastoma protein, and suppression of cyclin E. Decreased levels of phosphorylated Akt were also observed in lactoferrin-sensitive cell lines after treatment. These findings suggest that in head and neck cancer cells the growth inhibitory effects of lactoferrin are mediated through a p27/cyclin E-dependent pathway that may be modulated in part by changes in Akt phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623653     DOI: 10.1158/1078-0432.CCR-04-0988

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Does lactoferrin behave as an immunohistochemical oncofetal marker in bone and cartilage human neoplasms?

Authors:  Antonio Ieni; Valeria Barresi; Maddalena Grosso; Giuseppe Speciale; Michele A Rosa; Giovanni Tuccari
Journal:  Pathol Oncol Res       Date:  2010-10-24       Impact factor: 3.201

2.  Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin.

Authors:  Irini Bournazou; John D Pound; Rodger Duffin; Stylianos Bournazos; Lynsey A Melville; Simon B Brown; Adriano G Rossi; Christopher D Gregory
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

Review 3.  The role of talactoferrin alpha in the treatment of non-small cell lung cancer.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Expert Opin Biol Ther       Date:  2010-09       Impact factor: 4.388

4.  Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo.

Authors:  Jeffrey S Wolf; Guoyan Li; Atul Varadhachary; Karel Petrak; Mark Schneyer; Daqing Li; Julina Ongkasuwan; Xiaoyu Zhang; Rodney J Taylor; Scott E Strome; Bert W O'Malley
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

5.  Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis.

Authors:  Corey M Porter; Michael C Haffner; Ibrahim Kulac; Janielle P Maynard; Javier A Baena-Del Valle; William B Isaacs; Srinivasan Yegnasubramanian; Angelo M De Marzo; Karen S Sfanos
Journal:  Am J Pathol       Date:  2019-09-06       Impact factor: 4.307

6.  Lactotransferrin could be a novel independent molecular prognosticator of nasopharyngeal carcinoma.

Authors:  Wenling Zhang; Songqing Fan; Guoying Zou; Lei Shi; Zhaoyang Zeng; Jian Ma; Yanhong Zhou; Xiayu Li; Xinlin Zhang; Xiaoling Li; Ming Tan; Wei Xiong; Guiyuan Li
Journal:  Tumour Biol       Date:  2014-10-07

7.  Lactoferrin immuno-expression in human normal and neoplastic bone tissue.

Authors:  Antonio Ieni; Valeria Barresi; Maddalena Grosso; Michele Attilio Rosa; Giovanni Tuccari
Journal:  J Bone Miner Metab       Date:  2009-02-26       Impact factor: 2.626

8.  Recombinant human lactoferrin induces apoptosis, disruption of F-actin structure and cell cycle arrest with selective cytotoxicity on human triple negative breast cancer cells.

Authors:  Blanca F Iglesias-Figueroa; Tania S Siqueiros-Cendón; Denisse A Gutierrez; Renato J Aguilera; Edward A Espinoza-Sánchez; Sigifredo Arévalo-Gallegos; Armando Varela-Ramirez; Quintín Rascón-Cruz
Journal:  Apoptosis       Date:  2019-08       Impact factor: 4.677

9.  Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities.

Authors:  Sayuri Nakamura-Bencomo; Denisse A Gutierrez; Elisa Robles-Escajeda; Blanca Iglesias-Figueroa; Tania S Siqueiros-Cendón; Edward A Espinoza-Sánchez; Sigifredo Arévalo-Gallegos; Renato J Aguilera; Quintín Rascón-Cruz; Armando Varela-Ramirez
Journal:  Invest New Drugs       Date:  2020-10-16       Impact factor: 3.850

10.  Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas.

Authors:  A Ieni; V Barresi; G Branca; G Giuffrè; M A Rosa; G Tuccari
Journal:  Oncol Lett       Date:  2013-03-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.